MedTrace Logo

Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001

NCT03625934 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2021-04-06

No results posted yet for this study

Summary

The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to

* elicit a robust protective IgG immune response in vaccine naive subjects
* in subjects who failed to demonstrate seroconversion after treatment with a licensed hepatitis B vaccine and
* in patients chronically infected with HBV.

Conditions

Interventions

BIOLOGICAL

VVX001

5 s.c. injections of 20 micrograms of VVX001 four weeks apart

BIOLOGICAL

Placebo

5 s.c. injections of matching Placebo four weeks apart

Sponsors & Collaborators

  • Gouya Insights

    collaborator UNKNOWN

  • KKS MedUni Vienna

    collaborator UNKNOWN

  • Viravaxx AG

    lead INDUSTRY

Principal Investigators

  • Petra Munda, MD · Medical University Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-06
Primary Completion
2023-09-30
Completion
2023-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03625934 on ClinicalTrials.gov